From: Nanomedicine review: clinical developments in liposomal applications
LF | Active agent | Composition | Size (nm) | Indication | Status | References |
---|---|---|---|---|---|---|
ONPATTRO® | Patisiran (siRNA) | DLin-MC3-DMA, Cholesterol, DSPC, PEG2000-C-DMG | – | Hereditary transthyretin amyloidosis | Approved by FDA in August 2018 | (Anselmo and Mitragotri 2019) |
CPX-351 (Vyxeos™) | Daunorubicin + cytarabine | DSPC, DSPG, cholesterol (7:2:1) daunorubicin, cytarabine 5:1 | 100 | Acute myeloid leukemia | Approved by FDA in 2017 | (Ventola 2017; Lancet et al. 2014; Kaspers et al. 2013; Inman 2017) |
Onivyde® | Irinotecan + fluorouracil + folinic acid | PEGylated liposome | 80–140 | Pancreatic adenocarcinoma | Approved by FDA in 2015 | |
LEP-ETU | Paclitaxel | DOPC, cholesterol, cardiolipin (90:5:5) Lipid, PTX (33:1) | 150 | Ovarian cancer | Not approved by FDA | (Bozzuto and Molinari 2015; Bulbake et al. 2017; Slingerland et al. 2017) |
Marqibo® | Vincristine | Sphingomyelin, Cholesterol (60:40) | 100 | Non-Hodgkin’s lymphoma and leukemia | Approved by FDA in August 2012 | |
Exparel® | Bupivacaine | DEPC, DPPG, cholesterol, tricaprylin | 3000–30,000 | Pain management | Approved by FDA in 2011 | |
Mepact® | Mifamurtide | Non-PEGylated liposome, Muramyl tripeptide PE | – | Osteosarcoma | FDA denied approval 2007. This medicine is authorized for use in the European Union | |
Inflexal V® | Inactivated hemagglutinin of A or B influenza virus | DOPC, DOPE (75:25) | 150 | Influenza | Approved by European Medicines Agency (EMEA) in 2008 | |
Genexol-PM | Paclitaxel | PEG–PLA polymeric micelle | 20–50 | Breast, lung and ovarian cancer | Approved in Korea and marketed in Europe in 2007 | |
Epaxal® | Inactivated hepatitis A virus (strain RGSB) | DOPC, DOPE (75:25) | 150 | Hepatitis A | Approved in 2006 and is currently used in Switzerland and Argentina | |
Lipusu® | Paclitaxel | 72 g PC, 10.8 cholesterol in ethanol | 400 | Gastric, ovarian and lung cancer | Approved by FDA in 2005 | |
DepoDur™ | Morphine sulfate | Cholesterol, triolein, DOPC, DPPG (11:1:7:1) | 17,000–23,000 | Pain management | Approved by FDA in 2004 | |
Lipo-Dox® | Doxorubicin | DSPC, cholesterol, PEG 2000-DSPE (56:39:5) | 20 | Breast and ovarian cancer | Approved by FDA in 2012 | |
Myocet® | Doxorubicin + cyclophosphamide | EPC, cholesterol (55:45) | 190 | Metastatic breast cancer | Approved by EMEA in 2000 | |
Visudyne® | Verteporphin | EPG, DMPC (3:5) | 100 | Ocular histoplasmosis | Approved by FDA in 2000 | |
Depocyt® | Cytarabine | Cholesterol, triolein, DOPC, DPPG (11:1:7:1) | 20 | Neoplastic meningitis | FDA status: discontinued | |
Abelcet® | Amphotericin B | DMPC, DMPG (7:3) | 600–11,000 | Invasive fungal infection | Approval FDA in 1995 | |
Amphotec® | Amphotericin B | Cholesteryl sulfate | – | FDA status: discontinued | (Clemons and Stevens 2004) | |
DaunoXome® | Daunorubicin | DSPC, cholesterol, daunorubicin (10:5:1) | 45–80 | Leukemia | FDA status: discontinued | (Olusanya et al. 2018; Kraft et al. 2014; Kaspers et al. 2013) |
Doxil® | Doxorubicin | HSPC, cholesterol, PEG 2000-DSPE (56:39:5) | 100 | Kaposi’s sarcoma | Approved by FDA in 1995 | |
AmBisome® | Amphotericin B | HSPC, DSPG, cholesterol, amphotericin B (2:0.8:1:0.4) | 45–80 | Invasive fungal infection | Approved by FDA in 1997 | |
Thermodox® | Doxorubicin | DPPC, MSPC, PEG 2000-DSPE (90:10:14) | 175 | Hepatocellular carcinoma, solid tumors | Not approved | (Bozzuto and Molinari 2015; Lombardo et al. 2016; Chang and Yeh 2012) |
EndoTAG® | Paclitaxel | DOTAP, DOPC, PTX (50:47:3) | 180–200 | Breast cancer | Not approved | (Bozzuto and Molinari 2015; Bulbake et al. 2017; Strieth et al. 2013) |
MM-302 | Doxorubicin | DSPE, HER2, PEG | 75–110 | Breast cancer | Not approved | (Miller et al. 2016) |
PTX–LDE | Paclitaxel | 135 mg cholesteryl oleate, 333 mg egg PC, 132 mg miglyol 812 N, 6 mg cholesterol, 60 mg PTX | 1–1000 | Epithelial ovarian carcinoma | Not approved | |
Arikace® | Amikacin | DPPC, cholesterol (2:1) | ≈ 300 | Lung infections | Not approved | |
MRX34 | miR-34a | DOTAP, cholesterol | ≈ 110 | Advanced solid tumors and hematological malignances | Not approved | |
Xemys | Myelin basic proteins | Egg PC, monomannosyl dioleoyl glycerol, α-tocopherol and lactose | – | Multiple sclerosis | Not approved | (Jr et al. 2016) |